FASL Antikörper
Kurzübersicht für FASL Antikörper (ABIN187307)
Target
Alle FASL Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Spezifität
- This antibody is specific for the extracellular domain of human Fas Ligand. Species Reactivity: Human. Others not tested.
-
Immunogen
- Recombinant human FasL (extracellular domain)
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Functional Activity: Inhibits apoptosis in anti-CD3 stimulated Jurkat T-cells ( 0.5 ~ 5 µg/mL) suitable. Excellent for neutralization. Flow cytometry: 1 x 106 H9 T-cells stained with 1 µg/mL antibody, followed by biotinylated goat anti-mouse IgG and streptavidin-PE. Immunocytochemistry Suggested starting dilution is >1:100 The optimal dilution for a specific application should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Buffer
- 100 µg of 1 mg/mL affinity-purified monoclonal antibody. Prepared in 0.15M PBS, pH 7.2 with protein stabilizer. Purity 95% by SDS-PAGE.
-
Lagerung
- 4 °C
-
-
- FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))
-
Andere Bezeichnung
- CD178 / Fas Ligand
-
Hintergrund
- Fas (CD95/APO-1) Ligand (FasL) is a 43 kDa type II membrane protein and member of the tumor necrosis factor family. Human FasL can be released from cells as a 26 kDa soluble protein upon cleavage by metalloproteinases. FasL is expressed on various cells including T cells, NK cells, Monocytes, Sertoli cells and tumor cells. Interaction of FasL with its receptor triggers rapid apoptosis. FasL-induced apoptosis is involved in T cell receptor/anti-CD3 induced cell death, cytotoxic T cell activity, maintainence of immune privilege, immune escape of tumor cells and viral hepatitis. Malfunction of the Fas system causes hyperplasia.
-
Pathways
- Apoptose, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity
Target
-